Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 pivotal trial of intravitreal EYE103 versus ranibizumab for diabetic macular edema
MOH_2025-02-16_013610Phase 3Active, not recruiting
- Sponsor
- EyeBio
- Start
- Feb 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of restoret and ranibizumab in diabetic macular edema (DME) (3 arms), sponsored by EyeBio. Started Feb 2025; status: active, not recruiting.
02
Drugs
restoretranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2025-02-16_013610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-16_013610.